Functional decline slowing (≤2-point ALSFRS-R deterioration per month, preserved muscle strength in treated regions for ≥6 months) is reported in 35–50% of treated cohorts. Complete halting of disease progression is rare; survival extension beyond historical 2–3 year median remains unproven. Responders tend to be early-stage (symptom onset <18 months), younger (<60 years), and non-bulbar-onset phenotypes; rapidly progressive and bulbar-onset variants show lower response rates.
Clinical trial safety data across >500 ALS recipients shows no treatment-limiting adverse events from intrathecal or intravenous cell infusion. Efficacy signals emerge from small phase II cohorts: decline in ALSFRS-R (disease rating scale) is slowed by 30–50% over 12 months in 30–45% of treated patients versus untreated historical controls; some maintain muscle strength for 6–12 months longer than expected disease trajectory. Markers of neuroinflammation (CSF cytokine levels, microglial activation on PET imaging) decline in responder subgroups. No completed pivotal trial has demonstrated survival prolongation; two large multi-centre efficacy trials are recruiting.
我是候选人吗？ → · ALS (Motor Neurone Disease): full overview → · ALS（肌萎缩侧索硬化症）成本 → · Cost →
由 StemCellAtlas 的编辑团队进行医学审查，与Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估